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BACKGROUND: The phosphatidylinositol 30-kinase (PI3K)–AKT pathway is activated in many human cancers and plays a key role in cell
proliferation and survival. A mutation (E17K) in the pleckstrin homology domain of the AKT1 results in constitutive AKT1 activation by
means of localisation to the plasma membrane. The AKT1 (E17K) mutation has been reported in some tumour types (breast,
colorectal, ovarian and lung cancers), and it is of interest which tumour types other than those possess the E17K mutation.
METHODS: We analysed the presence of the AKT1 (E17K) mutation in 89 endometrial cancer tissue specimens and in 12 endometrial
cancer cell lines by PCR and direct sequencing.
RESULTS: We detected two AKT1 (E17K) mutations in the tissue samples (2 out of 89) and no mutations in the cell lines. These two
AKT1 mutant tumours do not possess any mutations in PIK3CA, PTEN and K-Ras.
INTERPRETATION: Our results and earlier reports suggest that AKT1 mutations might be mutually exclusive with other PI3K–AKT-
activating alterations, although PIK3CA mutations frequently coexist with other alterations (such as HER2, K-Ras and PTEN) in several
types of tumours.
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The AKT serine/threonine kinases regulate diverse cellular
processes, including cell survival, proliferation, invasion and
metabolism (Vivanco and Sawyers, 2002). The phosphatidylinosi-
tol 30-kinases (PI3Ks) are widely expressed lipid kinases that
catalyse the production of the second messenger phosphatidyli-
nositol 3,4,5-triphosphate (PIP3), which activates AKT by recruit-
ment to the plasma membrane through direct contact of its
pleckstrin homology (PH) domain (Stokoe et al, 1997; Lemmon
and Ferguson, 2000). Constitutive PI3K–AKT pathway activation
can result from various types of alterations in this pathway,
including mutation or amplification of receptor tyrosine kinases
(such as EGFR and HER2), mutation of Ras, mutation or
amplification of PIK3CA (the p110a catalytic subunit of PI3K)
and inactivation of the tumour suppressor gene, PTEN (Yuan and
Cantley, 2008). In addition to amplifications in multiple AKT
isoforms in pancreatic, ovarian and head and neck cancers
(Engelman et al, 2006), a somatic missense mutation in the PH
domain of AKT1 (E17K) was identified in breast, colorectal,
ovarian and lung cancers and in melanoma (Carpten et al, 2007;
Bleeker et al, 2008; Davies et al, 2008; Malanga et al, 2008).
However, the AKT1 mutation has not been identified in
hepatocellular, gastric and pancreatic cancers, leukemia, as well
as in glioblastoma multiforme (Bleeker et al, 2008; Cao et al, 2008;
Kim et al, 2008; Mahmoud et al, 2008; Mohamedali et al, 2008;
Riener et al, 2008; Zenz et al, 2008). Further study is required to
fully understand which tumour types take advantage of Akt1
(E17K) mutations to activate the PI3K–AKT pathway.
We reported earlier that PIK3CA mutations frequently coexist
with other PI3K-activating alterations in breast (with HER2 and
HER3) and endometrial cancers (with PTEN and K-Ras), and that
mutant p110a combined with mutant Ras efficiently transformed
immortalised human mammary epithelial cells (Oda et al, 2005,
2008). Frequent overlapping mutations of K-Ras and PIK3CA were
also reported in colorectal cancer (Parsons et al, 2005). Although
coexistent mutations of AKT1 and PIK3CA mutations are
suggested to be infrequent in breast cancer (Carpten et al, 2007;
Bleeker et al, 2008), it remains to be elucidated whether AKT1
mutations are mutually exclusive with all the other PI3K–AKT-
activating alterations in various tumour types.
Endometrial cancer is one of the tumour types in which the
PI3K–AKT pathway is frequently activated by alterations of various
genes. The frequency of mutations for PTEN, PIK3CA and K-Ras in
endometrial cancer is reported as 54, 28 and 11%, respectively
(Yuan and Cantley, 2008). In this study, we screened 89 endometrial
carcinoma specimens and 12 endometrial carcinoma cell lines for
mutations in Akt1 (E17K) and analysed whether AKT1 mutations
coexist with any mutations in PTEN, PIK3CA and K-Ras.
MATERIALS AND METHODS
Tumour samples and genomic DNA
Surgical samples were obtained from 89 patients with primary
endometrial carcinomas who underwent resection of their tumours
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sat the University of Tokyo Hospital. All patients provided
informed consent for the research use of their samples and the
collection, and the use of tissues for this study was approved by the
appropriate institutional ethics committees. Genomic DNA was
extracted by a standard SDS-proteinase K procedure. Patient
characteristics (histology, tumour grade and stage) are available in
Supplementary Table 1. A detailed distribution of the histological
subtypes was as follows; 81 (90%) endometrioid adenocarcinomas,
3 adenosquamous carcinomas, 1 clear cell carcinoma, 1 squamous
cell carcinoma and 3 mixed carcinomas.
PCR and sequencing
The primer sequences and PCR conditions of exon 4 of the AKT1
gene are forward: 50-CACACCCAGTTCCTGCCT G-30 and reverse:
50-CCTGGTGGGCAAAGAGGGCT-30. The PCR amplifications
were with denaturation at 941C for 5min, followed by 35 cycles
of 941C for 30s, 551C for 30s, 721C for 60s and final extension at
721C for 10min. The PCR conditions and the PCR primers for
PIK3CA (exons 9 and 20), PTEN (exons 1–9) and K-Ras (exons 1
and 2) were described earlier (Minaguchi et al, 2001; Samuels et al,
2004; Oda et al, 2008). The PCR products were sequenced using the
BigDye (Applied Biosystems, Foster City, CA, USA) terminator
method on an autosequencer.
Cell lines
In this study, AN3CA, KLE, HEC-1B and RL95-2 were obtained
from the American Type Culture Collection (Manassas, VA, USA)
and HHUA was obtained from the RIKEN CELL BANK (Tsukuba,
Japan). Ishikawa3-H-12 was a generous gift from Dr Masato
Nishida (Kasumigaura Medical Center, Ibaraki, Japan). HEC-6,
HEC-50B, HEC-59, HEC-88, HEC-108 and HEC-116 cell lines were
also analysed in this study. The culture condition of all these cell
lines was described earlier (Oda et al, 2008).
DNA methylation analysis
Bisulphite treatment was performed using the EZ DNA methyla-
tion kit (Zymo Research, Orange, CA, USA). As described earlier
(Ehrich et al, 2006), we used Sequenom’s MassARRAY platform to
perform quantitative methylation analysis of multiple CpG sites for
PTEN in 53 endometrial tumour specimens (Sequenom, San Diego,
CA, USA). Chromosomal localisation of CpG islands for PTEN and
the primer sequences in this study are shown in Supplementary
Figure 1.
Immunohistochemistry (IHC)
Immunohistochemistry for PTEN on 4-mm tissue sections was
performed and evaluated as described earlier (Minaguchi et al,
2007). In this study, the anti-PTEN Rabbit monoclonal antibody
(138G6) (Cell Signaling, Beverly, MA, USA) was applied at a
dilution of 1:100.
Single nucleotide polymorphism (SNP) array
Single nucleotide polymorphism array was performed in the two
AKT1 mutant tumours with tumour DNA. Experimental proce-
dures for GeneChip were performed according to GeneChip
Expression Analysis Technical Manual (Affymetrix, Santa Clara,
CA, USA), using a Human mapping 50K Array Xba I (Affymetrix).
RESULTS AND DISCUSSIONS
The sequencing analysis for exon 4 of the AKT1 gene in 89 tumour
tissue samples of endometrial carcinomas showed the point
mutation of G to A at nucleotide 49 (E17K) in two tissue samples
(2.2%) (Figure 1). Both of the tumours were well-differentiated
endometrioid adenocarcinomas with positive oestrogen receptor
and progesterone receptor, suggesting that these two tumours are
oestrogen dependent (corresponded to type I endometrial cancer).
No mutations were detected in the 12 endometrial cancer cell lines.
Thereafter, we attempted to figure out the exclusivity of AKT1
mutations and other PI3K–AKT-activating mutations (Supple-
mentary Table 1). The genotypic pattern of the four genes (PTEN,
PIK3CA, K-Ras and AKT1) in 97 endometrial carcinomas (85
tumour tissue samples and 12 cell lines) was shown in Table 1.
Coexistence with other mutations is frequently observed in the
PIK3CA mutant (28 of 34; 82%) and in the K-Ras mutant (13 out of
17; 76%) tumours, but the two AKT1 mutant tumours do not
possess any mutations in PTEN, PIK3CA and K-Ras. As PI3K and
Control
Tumour-1
Tumour-2
E17K (Nucleotide: 49G>A)
G GGGG G CC T A TT AA A A A
GG G GG
G
CC T A TT AA A A A A
GG G G GCC T A TT AA A A A A
Figure 1 The sequence traces of two tumours and a normal control for
exon 4 of AKT1. The E17K mutation is caused by a missense mutation (G
to A) indicated. In tumour-2, the level of the mutant band (A) is much
higher than that of the wild-type band (G). It is possible that this weak band
is derived from DNA of normal cells and that the tumour might lose one
allele at this locus.
Table 1 PI3K–AKT activating mutations and their coexistence in 97
endometrial cancers
n (%)
Wild-type 24 (25)
AKT1 mutation alone 2 (2)
K-Ras mutation alone 4 (4)
PIK3CA mutation alone 6 (6)
PTEN mutation alone 30 (31)
Double mutations of K-Ras and PIK3CA (w/o PTEN mutation) 2 (2)
Double mutations of K-Ras and PTEN (w/o PIK3CA mutation) 3 (3)
Double mutations of PIK3CA and PTEN (w/o K-Ras mutation) 18 (19)
Triple mutations of K-Ras, PIK3CA and PTEN 8 (8)
PI3K, phosphatidylinositol 30-kinase. Wild-type, no mutations in PTEN, PIK3CA, K-Ras
and AKT1.
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sPTEN are competitive for PIP3 production, the PIK3CA mutation
might require another upstream input or PTEN loss itself to fully
activate the PI3K–AKT pathway. As AKT1 (E17K) functions
downstream of PTEN and shows constitutive localisation to the
plasma membrane in the absence of serum stimulation (Carpten
et al, 2007), mutant AKT1 (E17K) alone might be sufficient for
complete activation of this pathway.
We also analysed DNA methylation and protein expression of
PTEN, as hypermethylation and loss of heterozygosity (LOH) are
other mechanisms to inactivate PTEN (Teng et al, 1997; Blanco-
Aparicio et al, 2007). Quantitative analysis of DNA methylation
using Sequenom’s MassARRAY platform did not find promoter
hypermethylation of PTEN in all the 53 samples that were
examined (Supplementary Figure 2 and Supplementary Table 2),
including the two AKT1 mutant tumours. Although PTEN
methylation had been reported in 18% of endometrial carcinomas
(Salvesen et al, 2001), Zysman et al (2002) suggested that the
pseudogene on chromosome 9 (Genbank accession number:
AF040103), not PTEN, is predominantly methylated in endometrial
carcinomas. In IHC, both tumours with the AKT1 mutation were
stained positively for PTEN in the cytoplasm, whereas all the four
tumours with multiple frameshift mutations in PTEN were
stained negatively (Supplementary Figure 3). We evaluated the
chromosomal imbalances in the two AKT1 mutant tumours,
using SNP array (with more than 50000 SNPs). Single nucleo-
tide polymorphism array analysis showed that the two AKT1
mutant tumours do not show copy number changes in the locus
of PTEN (10q23.1) (data not shown). These data also support the
fact that AKT1 mutations are mutually exclusive with PTEN
inactivation.
We found multiple PTEN mutations in 13 out of 85 clinical
specimens and in 8 out of 12 endometrial cell lines (Supplementary
Table 1), whereas LOH of PTEN was reported approximately at
30% in endometrial carcinomas (Toda et al, 2001). Thus, biallelic
PTEN inactivation might be achieved through either biallelic
mutations or monoallelic mutation with LOH in endometrial
carcinomas. Considering the correlation between PTEN mutations
and microsatellite instability (MSI) in endometrial carcinomas
(Bilbao et al, 2006), it would be of interest to analyse whether
AKT1 and the other mutations in the PI3K pathway genes are also
associated with MSI.
To date, AKT1 (E17K) mutations have been reported in breast
(25 out of 427; 5.9%), colorectal (4 out of 243; 1.6%), lung (4 out of
636; 0.6%) and ovarian cancers (1 out of 130; 0.8%) and in
melanoma (1 out of 202; 0.5%). Breast, colorectal and endometrial
cancers are the tumour types that frequently possess PIK3CA
mutations (Campbell et al, 2004; Samuels et al, 2004; Oda et al,
2005). In lung cancer, the AKT1 mutation was detected only in
squamous cell carcinomas and not in any adenocarcinomas, which
is in agreement with the higher incidence of PIK3CA mutations or
amplifications in squamous cell carcinomas than adenocarcinomas
(Kawano et al, 2006, 2007; Malanga et al, 2008). These data suggest
that the AKT1 mutation might occur in a tissue-specific manner
and is more associated with the tumour types with frequent
PIK3CA alterations.
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